Dexrazoxane
- Generic Name
- Dexrazoxane
- Brand Names
- Savene, Totect, Zinecard
- Drug Type
- Small Molecule
- Chemical Formula
- C11H16N4O4
- CAS Number
- 24584-09-6
- Unique Ingredient Identifier
- 048L81261F
- Background
An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem]
The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.
- Indication
For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.
- Associated Conditions
- Doxorubicin Induced Cardiomyopathy, Drug Extravasation
Treatment of Childhood Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 491
- Registration Number
- NCT00165087
- Locations
- 🇺🇸
Ochsner Clinic, New Orleans, Louisiana, United States
🇨🇦McMaster University, Hamilton, Ontario, Canada
🇺🇸Maine Medical Center, Lewiston, Maine, United States
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- Biological: epratuzumabBiological: filgrastim
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 134
- Registration Number
- NCT00098839
- Locations
- 🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma
- Conditions
- Sarcoma
- First Posted Date
- 2004-06-24
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003667
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
- Conditions
- Central Nervous System Tumor, Pediatric
- Interventions
- Biological: filgrastimRadiation: radiation therapy
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT00084838
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, United States
Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
- Conditions
- Cardiac ToxicityLymphoma
- Interventions
- Biological: bleomycin sulfateBiological: filgrastimRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET electron therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 294
- Registration Number
- NCT00002827
- Locations
- 🇺🇸
Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Long Beach Memorial Medical Center, Long Beach, California, United States
Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease
- Conditions
- LymphomaCardiac Toxicity
- Interventions
- Biological: bleomycin sulfateBiological: filgrastimRadiation: radiation therapy
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 219
- Registration Number
- NCT00005578
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Simmons Cancer Center - Dallas, Dallas, Texas, United States
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
- Conditions
- Sarcoma
- Interventions
- Procedure: conventional surgeryRadiation: radiation therapy
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT00077285
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
- Conditions
- Cardiac ToxicitySarcoma
- Interventions
- First Posted Date
- 2004-02-09
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 253
- Registration Number
- NCT00003937
- Locations
- 🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
- Conditions
- Cardiac ToxicityInflammatory Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IV Breast Cancer
- Interventions
- Biological: trastuzumabProcedure: therapeutic conventional surgeryRadiation: radiation therapyOther: laboratory biomarker analysis
- First Posted Date
- 2003-09-04
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 396
- Registration Number
- NCT00016276
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma
- Conditions
- Cardiac ToxicitySarcoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00019864
- Locations
- 🇺🇸
Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.